Progress on anti-programmed cell death protein-1 immunotherapy for chronic virus infection

doi:10.3877/cma.j.issn.1674-1358.2020.05.002

Abstract

Abstract:

Immune system plays a pivotal role in disease development during chronic virus infection. On one hand, the immune system defends against infectious agents through effector immune cells and molecules. On the other hand, the immune system has negative immune regulation mechanisms to suppress immune response and prevent its overactivation. However, these mechanisms may oversuppress and hamper the generation of effective antiviral immune responses during chronic viral infection. In this review, the function of immunosuppressive molecules programmed cell death protein-1 (PD-1) and its ligand PD-L1 during chronic viral infections were discussed, and recent advances in immune therapies targeting these molecules were summarized.

Key words: Programmed cell death protein-1, Immunotherapy, Chronic virus infection

Ziwei Li, Dongliang Yang, Jia Liu. Progress on anti-programmed cell death protein-1 immunotherapy for chronic virus infection[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2020, 14(05): 361-366.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2020.05.002

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2020/V14/I05/361

Figures/Tables 1

References 62

[1]	Moreno-Cubero E, del Arco RTS, Pena-Asensio J, et al. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?[J]. World J Gastroenterol,2018,24(17):1825-1838.
[2]	WHO. Global hepatitis report 2017:1-83. URL
[3]	Collaborators GH. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017[J]. Lancet HIV,2019,6(12):e831-e859.
[4]	Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J,1992,11(11):3887-3895.
[5]	Dermani FK, Samadi P, Rahmani G, et al. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy[J]. J Cell Physiol, 2019,234(2):1313-1325.
[6]	Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation[J]. J Immunol,2004,173(2):945-954.
[7]	Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J]. Cell Immunol,2014,290(1):72-79.
[8]	Zhang X, Schwartz JC, Guo X, et al. Structural and functional analysis of the costimulatory receptor programmed death-1[J]. Immunity,2004,20(3):337-347.
[9]	Saresella M, Rainone V, Al-Daghri NM, et al. The PD-1/PD-L1 pathway in human pathology[J]. Curr Mol Med,2012,12(3):259-267.
[10]	Shinohara T, Taniwaki M, Ishida Y, et al. Structure and chromosomal localization of the human PD-1 gene (PDCD1)[J]. Genomics,1994,23(3):704-706.
[11]	Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity[J]. Autoimmun Rev,2013,12(11):1091-1100.
[12]	Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med,1999,5(12):1365-1369.
[13]	Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol,2008,26:677-704.
[14]	Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer,2012,12(4):252-264.
[15]	Hebeisen M, Baitsch L, Presotto D, et al. SHP-1 phosphatase activity counteracts increased T cell receptor affinity[J]. J Clin Invest,2013,123(3): 1044-1056.
[16]	Chikuma S, Terawaki S, Hayashi T, et al. PD-1-mediated suppression of IL-2 production induces CD8⁺ T cell anergy in vivo[J]. J Immunol,2009,182(11):6682-6689.
[17]	Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2[J]. J Exp Med,2012,209(6):1201-1217.
[18]	Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity[J]. Curr Top Microbiol Immunol,2011,350:17-37.
[19]	Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer[J]. Annu Rev Immunol,2016,34:539- 573.
[20]	Wherry EJ. T cell exhaustion[J]. Nat Immunol,2011,12(6):492- 499.
[21]	Buermann A, Romermann D, Baars W, et al. Inhibition of B-cell activation and antibody production by triggering inhibitory signals via the PD-1/PD-ligand pathway[J]. Xenotransplantation,2016,23(5):347- 356.
[22]	Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8⁺ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J]. J Hepatol,2014,61(6):1212-1219.
[23]	Raziorrouh B, Heeg M, Kurktschiev P, et al. Inhibitory phenotype of HBV-specific CD4⁺ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules[J]. PLoS One,2014,9(8):e105703.
[24]	Huang ZY, Xu P, Li JH, et al. Clinical significance of dynamics of programmed death ligand-1 expression on circulating CD14(+) monocytes and CD19(+) B cells with the progression of hepatitis B virus infection[J]. Viral Immunol,2017,30(3):224-231.
[25]	Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection[J]. J Clin Invest,2018,128(10):4573-4587.
[26]	Zhang Z, Zhang JY, Wherry EJ, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B[J]. Gastroenterology,2008,134(7):1938-1949, e1-3.
[27]	Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection[J]. J Virol,2007,81(8):4215-4225.
[28]	Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B[J]. Gastroenterology,2010,138(2):682-693, e1-4.
[29]	Burton AR, Pallett LJ, McCoy LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B[J]. J Clin Invest,2018,128(10):4588-4603.
[30]	Zhang E, Zhang X, Liu J, et al. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection[J]. PLoS One,2011,6(10):e26196.
[31]	Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection[J]. PLoS Pathog,2014,10(1):e1003856.
[32]	Gane E, Gaggar A, Nguyen A H, et al. A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients[J]. J Hepatol,2017,66(1):S26-S27.
[33]	Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study[J]. J Hepatol,2019,71(5):900-907.
[34]	Barathan M, Mohamed R, Vadivelu J, et al. CD8⁺ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides[J]. Cell Immunol,2017,313:1-9.
[35]	Cho H, Kang H, Lee HH, et al. Programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis[J]. Int J Mol Sci,2017,18(7):1517.
[36]	Wang W, Tong Z, Zhong J, et al. Identification of IL-10-secreting CD8(+)CD28(-)PD-1(+) regulatory T cells associated with chronic hepatitis C virus infection[J]. Immunol Lett,2018,202:16-22.
[37]	Ojiro K, Qu X, Cho H, et al. Modulation of hepatitis C virus-specific CD8 effector T-cell function with antiviral effect in infectious hepatitis C virus coculture model[J]. J Virol,2017,91(10):e02129-16.
[38]	Fuller MJ, Callendret B, Zhu B, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1) [J]. Proc Natl Acad Sci USA,2013,110(37):15001-15006.
[39]	Nakamoto N, Cho H, Shaked A, et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade[J]. PLoS Pathog,2009,5(2):e1000313.
[40]	Gardiner D, Lalezari J, Lawitz E, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection[J]. PLoS One,2013,8(5):e63818.
[41]	Cox MA, Nechanitzky R and Mak TW. Check point inhibitors as therapies for infectious diseases[J]. Curr Opin Immunol,2017,48:61- 67.
[42]	Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8⁺ T cells leads to reversible immune dysfunction[J]. Nat Med,2006,12(10):1198-1202.
[43]	Chew GM, Fujita T, Webb GM, et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection[J]. PLoS Pathog,2016,12(1):e1005349.
[44]	Ghiglione Y, Trifone C, Salido J, et al. PD-1 expression in HIV-specific CD8⁺ T-cells prior to antiretroviral therapy is associated with HIV persistence[J]. J Acquir Immune Defic Syndr,2018,80(1):1-6.
[45]	Hoang TN, Harper JL, Pino MC, et al. Bone marrow-derived CD4(+) T cells are depleted in SIV-infected macaques and contribute to the size of the replication competent reservoir on ART[J]. J Virol,2018,93(1):e01344-18.
[46]	Leon-Flores A, Del Rio Estrada PM, Alvarez-Garcia LX, et al. Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1(+) individuals[J]. Immunol Lett,2018,203:70-79.
[47]	Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression[J]. Nature,2006,443(7109):350-354.
[48]	Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8(+) T cell survival in HIV infection[J]. J Exp Med,2006,203(10):2281-2292.
[49]	Mylvaganam GH, Chea LS, Tharp GK, et al. Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV[J]. JCI Insight,2018,3(18):e122940.
[50]	Gill AL, Green SA, Abdullah S, et al. Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab)[J]. AIDS,2016,30(16):2487-2493.
[51]	Grabmeier-Pfistershammer K, Stecher C, Zettl M, et al. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade[J]. Clin Immunol,2017,183:167-173.
[52]	Plachouri KM, Vryzaki E, Georgiou S. Cutaneous adverse eents of immune checkpoint inhibitors: A summarized overview[J]. Curr Drug Saf,2019,14(1):14-20.
[53]	Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the FDA database and review[J]. Eur J Haematol,2019,102(2):157-162.
[54]	Nishino M, Ramaiya NH, Awad MM, et al. PD-1 Inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course[J]. Clin Cancer Res,2016,22(24):6051-6060.
[55]	Widmann G, Nguyen VA, Plaickner J, et al. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy[J]. Curr Radiol Rep,2016,5(11):59.
[56]	Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade[J]. J Thorac Dis,2018,10(Suppl 3):S480-S489.
[57]	Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors[J]. Cancer Treat Rev,2016,44:51-60.
[58]	Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer,2017,5(1):95.
[59]	Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens A systematic review and Meta-analysis[J]. JAMA Oncol,2018,4(2):173-182.
[60]	Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy[J]. Diabetes Care,2015,38(4):e55-e57.
[61]	Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature[J]. Ann Oncol,2017,28(2):377-385.
[62]	Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer[J]. JAMA Neurol,2016,73(8):928-933.

病原体	受影响免疫细胞类型	研究对象	主要研究进展
乙型肝炎病毒	CD4⁺ T细胞、CD8⁺ T细胞、MBCs、B细胞等	小鼠、土拨鼠、人	阻断PD-1/PD-L1能改善CD4⁺ T细胞、CD8⁺ T细胞、MBCs及B细胞功能，抑制病毒复制，增强抗体产生
丙型肝炎病毒	CD4⁺ T细胞、CD8⁺ T细胞等	细胞、黑猩猩、人	阻断PD-1能部分改善HCV特异性T细胞功能；联合阻断PD-1/CTLA-4能获得更好的阻断作用
人类免疫缺陷病毒	CD4⁺ T细胞、CD8⁺ T细胞、B细胞等	恒河猴、人	阻断PD-1能提高HIV特异性CD8⁺ T细胞功能；PD-1阻断参与的联合治疗能推迟病毒反弹

病原体	受影响免疫细胞类型	研究对象	主要研究进展
乙型肝炎病毒	CD4⁺ T细胞、CD8⁺ T细胞、MBCs、B细胞等	小鼠、土拨鼠、人	阻断PD-1/PD-L1能改善CD4⁺ T细胞、CD8⁺ T细胞、MBCs及B细胞功能，抑制病毒复制，增强抗体产生
丙型肝炎病毒	CD4⁺ T细胞、CD8⁺ T细胞等	细胞、黑猩猩、人	阻断PD-1能部分改善HCV特异性T细胞功能；联合阻断PD-1/CTLA-4能获得更好的阻断作用
人类免疫缺陷病毒	CD4⁺ T细胞、CD8⁺ T细胞、B细胞等	恒河猴、人	阻断PD-1能提高HIV特异性CD8⁺ T细胞功能；PD-1阻断参与的联合治疗能推迟病毒反弹

Please choose a citation manager

Content to export